We are a leader in China’s pharmaceutical industry. At present, we have already regarded as top five domestic Pharmaceutical company in China（IQVIA）. In 2017, our revenue from pharmaceutical manufacturing and R&D amounted to approximately RMB13,195million, growing by 28.62% year-over-year.
At present, Fosun Pharma maintains the leading position with its core products in various therapeutic areas, including oncology, cardiovascular system, central nervous system, blood system, metabolism and alimentary system and anti-infection. All products occupy the leading position in each market segment and maintain the rapid growth in sales of those major products. In 2017, a total of 21 formulation items or series were sold over RMB100 million.
About other business of Fosun Pharma